EUVIMEDEUVIMED entdecken
Crossref

UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas

Zhonglan Dong, Wenbai Huang, Lei Zhang, Qianru Guo, Xiaobei Zhang, Yang Yang, Xudong Wang, Zhihua Liu, Yiqing Yin, Gang Ma

Cancer Letters · 2026-12 · 662 · 218905

DOI: 10.1016/j.canlet.2026.218905 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-12. Verfasst von Zhonglan Dong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Department of Cancer Neuroscience, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research C…. Hauptthemen laut MEDLINE: DNA Polymerase II, Esophageal Squamous Cell Carcinoma, Ubiquitins, Carcinoma, Squamous Cell. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While immune checkpoint inhibitors (ICIs) have revolutionized treatment of the patients with aero-upper digestive squamous cell carcinomas (SCCs), including esophageal squamous cell carcinoma (ESCC) and lung squamous cell carcinoma (LUSC), only a subset of patients benefit from ICIs, therefore entailing exploration of the mechanisms to regulate treatment responsiveness. POLE, as a subunit of DNA polymerase ε, possesses 3'-5' proofreading activity, and its mutations have been associated with favourable response to ICIs in several solid tumors. However, post-translational modification (PTM) of POLE and its impact on the therapeutic efficacy of ICIs are unknown. Here, this study demonstrates that ubiquitin-like protein 3 (Ubl3), whose expression is markedly downregulated in SCCs, covalently binds to Pole, reduces nuclear Pole levels, triggers DNA damage, and activates cGAS-STING signaling pathway. Notably, Ubl3 modification of Pole significantly primes the local immune microenvironment to mitigate the growth of murine aero-upper digestive SCC cells and boost the efficacy of αPD-1 treatment in vivo. Single-cell RNA sequencing (scRNA-seq) analysis further revealed that UBL3 expression is positively correlated with better clinical outcomes in a cohort of ESCC patients receiving neoadjuvant chemotherapy combined with αPD-1. Together, our findings unravel UBL3 modification as a novel PTM mechanism governing subcellular location of POLE and its influence on immunotherapy responsiveness, thus making UBL3 modification as a promising immunomodulatory approach to enhance immunotherapy efficacy in patients with aero-upper digestive SCCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA Polymerase IIEsophageal Squamous Cell CarcinomaUbiquitinsCarcinoma, Squamous CellEsophageal NeoplasmsHumansAnimalsMiceCell Line, TumorcGAS-STING Signaling PathwayDNA DamageTumor MicroenvironmentCell NucleusFemaleProtein Processing, Post-TranslationalGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Aero-upper digestive squamous cell carcinomasAntitumor immunityImmune checkpoint inhibitorsPOLE/PoleUBL3/Ubl3

Substanzen

DNA Polymerase IIUbiquitins

Autor:innen und Institutionen

  • Department of Anesthesiology, Department of Cancer Neuroscience, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China; Tianjin Key Laboratory of…
  • Department of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China; Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060…
  • Burning Rock Biotech, Guangzhou, 510300, PR China. Electronic address: lei.zhang@brbiotech.com.
  • Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China; Tianjin Key Laboratory of Digestive Cancer, Tianjin, 300060, PR C…
  • Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, PR China; Tianjin Key Laboratory of…
  • State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, PR…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Dong, Z., Huang, W., Zhang, L., Guo, Q., Zhang, X., Yang, Y., Wang, X., Liu, Z., Yin, Y., & Ma, G. (2026). UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas. Cancer Letters, 662, 218905. https://doi.org/10.1016/j.canlet.2026.218905

Vancouver

Dong Z, Huang W, Zhang L, Guo Q, Zhang X, Yang Y, et al. UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas. Cancer Letters. 2026;662:218905. doi:10.1016/j.canlet.2026.218905

BibTeX
@article{Dong2026,
  author = {Dong, Zhonglan and Huang, Wenbai and Zhang, Lei and Guo, Qianru and Zhang, Xiaobei and Yang, Yang and Wang, Xudong and Liu, Zhihua and Yin, Yiqing and Ma, Gang},
  title = {UBL3 modification reduces nuclear POLE levels to potentiate antitumor immunity in aero-upper digestive squamous cell carcinomas},
  journal = {Cancer Letters},
  year = {2026},
  volume = {662},
  pages = {218905},
  doi = {10.1016/j.canlet.2026.218905}
}
Kostenlos starten →